|
MechanismGRPR antagonists |
|
|
|
|
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Efficacy, Safety and Tolerability, of ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
This trial will evaluate the effect of ASP7147 on daily abdominal pain due to IBS-D during 4 weeks of treatment. It will also evaluate safety and tolerability in patients with IBS-D over the 4-week treatment period.
100 Clinical Results associated with Seldar Pharma, Inc.
0 Patents (Medical) associated with Seldar Pharma, Inc.
100 Deals associated with Seldar Pharma, Inc.
100 Translational Medicine associated with Seldar Pharma, Inc.